Receive our newsletter – data, insights and analysis delivered to you

France accounts for 4.1% share of global clinical trial activity in 2020

By johanna swanson

France has accounted for a 4.1% share of the global clinical trials activity in 2020, registering a decrease when compared with the last ten-year average of a 5.3% share, according to GlobalData.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Industry sponsored trials outnumber non-industry sponsored trials in France

Industry sponsored trials held a 69.0% share of all the clinical trials in France in 2020, when compared with the ten-year average of 75.3%. Non-industry sponsored trials accounted for a 31.0% share in 2020 as against the average of 24.7% in the last ten years.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Top therapy areas for industry sponsored clinical trials in France

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Oncology was the leading therapy area for industry sponsored clinical trials in France in 2020 with a 41.6% share, as against a five-year average of 43.5% and a ten-year average of 40.7%.

Infectious Disease held a 14.4% share in 2020, over a five-year average of 6.6% and a ten-year average of 8.5%.

Central Nervous System held a 9.7% share in 2020, compared to a five-year average of 10.7% and a ten-year average of 11.4%. Respiratory held a 7.3% share in 2020, as against a five-year average of 4.4% and a ten-year average of 4.7%.

Cardiovascular held a 6.2% share, over a five-year average of 6.1% and a ten-year average of 6.7%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Top therapy areas for non-industry sponsored clinical trials in France

Infectious Disease was the leading therapy area for non-industry sponsored clinical trials in France in 2020 with a 37.5% share, as against a five-year average of 11.4% and a ten-year average of 10.9%.

Oncology held a 23.3% share in 2020, over a five-year average of 27.1% and a ten-year average of 28.2%.

Respiratory held a 15.2% share in 2020, compared to a five-year average of 4.2% and a ten-year average of 4.0%. Cardiovascular held a 12.0% share in 2020, as against a five-year average of 12.8% and a ten-year average of 12.1%.

Central Nervous System held an 11.7% share, over a five-year average of 22.1% and a ten-year average of 23.0%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Phase III trials lead industry sponsored clinical trials in France in 2020

Phase III trials held a 44.0% share of industry sponsored clinical trials in France in 2020, over a five-year average of 42.8% and a ten-year average of 43.0%.

Phase II trials held a 38.9% share in 2020, as against a five-year average of 39.3% and a ten-year average of 37.2%. Phase I trials held an 8.7% share in 2020, compared to a five-year average of 8.9% and a ten-year average of 9.4%.

Phase IV trials held an 8.4% share in 2020, over a five-year average of 9.1% and a ten-year average of 10.4%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Phase II trials lead non-industry sponsored clinical trials in France in 2020

Phase II trials held a 44.5% share of non-industry sponsored clinical trials in France in 2020, over a five-year average of 42.7% and a ten-year average of 42.3%.

Phase III trials held a 33.2% share in 2020, as against a five-year average of 28.9% and a ten-year average of 27.4%. Phase IV trials held a 19.1% share, compared to a five-year average of 25.1% and a ten-year average of 24.8%.

Phase I held a 3.2% share in 2020, over a five-year average of 3.3% and a ten-year average of 5.5%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Methodology:

The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU